CDK4 and neoplasm: Overall, while CDK4/6 inhibitors offer selective targeting with manageable toxicity, Dinaciclib’s broader inhibition spectrum provides more robust anti-cancer effects, particularly in OSCC, in which multiple CDK-related pathways contribute to tumor progression.